Compagnie Lombard Odier SCmA’s Neurocrine Biosciences NBIX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-149,864	Closed	-$14.6M	–	674
2021 Q1	$14.6M	Buy	+149,864	New	+$15.7M	0.32%	64
2017 Q2	–	Sell	-260	Closed	-$11K	–	741
2017 Q1	$11K	Hold	260	–	–	﹤0.01%	670
2016 Q4	$10K	Hold	260	–	–	﹤0.01%	750
2016 Q3	$13K	Hold	260	–	–	﹤0.01%	826
2016 Q2	$12K	Hold	260	–	–	﹤0.01%	819
2016 Q1	$10K	Buy	+260	New	+$10.3K	﹤0.01%	886
2014 Q1	–	Sell	-3,980	Closed	-$37K	–	890
2013 Q4	$37K	Buy	+3,980	New	+$38.8K	﹤0.01%	730

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

DCP

DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

Compagnie Lombard Odier SCmA's NBIX Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 149,864 shares — an estimated $14.6M sold.

Compagnie Lombard Odier SCmA first reported a position in NBIX in Q4 2013 and held it in 7 quarters. The position peaked at $14.6M in Q1 2021. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

Compagnie Lombard Odier SCmA reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 149,864 Neurocrine Biosciences shares in Q2 2021, an estimated $14.6M.
Compagnie Lombard Odier SCmA first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 7 quarters.
Compagnie Lombard Odier SCmA's Neurocrine Biosciences position peaked at $14.6M in Q1 2021.
408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.